| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8958404 | Journal of Thoracic Oncology | 2018 | 33 Pages |
Abstract
RTK and BRAF fusions are rare but potentially druggable resistance mechanisms to EGFR TKIs. Detection of RTK and BRAF fusions should be part of comprehensive profiling panels to determine resistance to EGFR TKIs and direct appropriate combination therapeutic strategies.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Alexa B. PhD, Viola W. MD, PhD, Wen-Son MD, PhD, Russell BS, Benjamin MD, Jeffrey MD, Dan MD, Anjali MD, Ioana MD, Thangavijayan MD, Petros MD, Jeffrey S. MD, Vincent A. MD, Siraj M. MD, PhD, Samuel J. MD, Sai-Hong Ignatius MD, PhD,